United Therapeutics (UTHR) Q2 2025 earnings summary

Executive summary

• Achieved record total revenue of $799 million for Q2 2025, up 12% year-over-year, marking 12 consecutive quarters of double-digit growth, driven by Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin.

• Board authorized up to $1 billion in share repurchases through March 2026, reflecting confidence in business outlook and capital strength.

• Strong commercial execution with record patient shipments and highest quarterly revenues for key products.

• Net income for Q2 2025 was $309.5 million, up from $278.1 million in Q2 2024; diluted EPS rose to $6.41 from $5.85.

• Late-stage clinical pipeline progressing, with key data readouts expected in 2025 and 2026.

Financial highlights

• Total revenue reached $799 million, up 12% year-over-year from Q2 2024.

• Tyvaso DPI revenue was $315.2 million, up 22% year-over-year; total Tyvaso (DPI and Nebulized) revenue rose 18% to $469.6 million.

• Orenitram revenue increased 16% to $123.9 million; Unituxin up 13% to $58.4 million.

• Remodulin revenue declined 9% to $134.7 million, reflecting ongoing generic competition.

• Cash, cash equivalents, and marketable investments totaled $4.97 billion as of June 30, 2025.

Outlook and guidance

• Management expects continued double-digit revenue growth for Tyvaso and total revenues, supported by commercial execution and late-stage pipeline.

• TETON-2 study in idiopathic pulmonary fibrosis (IPF) to report data in September 2025; TETON-1 data expected in first half of 2026.

• Regulatory filing for IPF indication planned if both TETON studies are successful, targeting commercial launch by 2027.

• Ralinepag ADVANCE OUTCOMES study fully enrolled; data expected in 2026.

• $710 million budgeted for capital expenditures through 2027, focused on manufacturing and xenotransplantation facilities.